Grants for Public Housing Authorities

This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS). The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing that could be used to satisfy the requirements for FDA approval of MUMS-designated drugs.Only entities developing drugs for veterinary use or parties working as research partners with such entities are eligible for grants.The organization (or applicant) seeking approval of the new animal drug under investigation must have opened an Investigational New Animal Drug (INAD) file with FDA/CVM and must hold a minor use or minor species "designation" granted by FDA/CVM's Office of Minor Use and Minor Species Animal Drug Development (OMUMS) for that drug for a specified intended use, in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516.FDA/CVM's Office of New Animal Drug Evaluation (ONADE) must have reviewed and concurred with the proposed study protocol before an applicant can submit a grant application.

This grant provides funding to develop and share essential resources and services that support alcohol-related biomedical research for scientists across the country.

This funding opportunity supports researchers working to identify and address health and healthcare disparities affecting sexual and gender minority populations, particularly those from racial/ethnic minority and lower socioeconomic backgrounds.

Addressing the Impact of Syndemics on the Health of People with HIV and Diseases and Conditions within the Missions of NIDDK and NHLBI (R01 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) invites applications for a cooperative agreement to support, manage and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation to 1) support efforts to accelerate drug product development; 2) support approaches to advanced manufacturing; 3) facilitate translation of basic science discoveries into therapeutics; and 4) facilitate approaches to enhance the safety, efficacy, quality, and performance of drug products. Projects are identified by FDA. Multiple awards may be funded under this NOFO and are directly dependent on drug development priorities and subject to the availability of funding.

The "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that further develop and validate innovative technologies for analyzing molecular and cellular aspects of cancer, with the goal of improving cancer research, detection, diagnosis, treatment, and understanding of health disparities.

FDA announces the availability of fiscal year (FY) 2024 funds to support one or more projects to 1) collect antimicrobial use data from diverse animal sectors, including domestic livestock, poultry, companion animals (dogs, cats, and horses), and minor species (e.g., fish, sheep, goats, etc.) and 2) contribute to the development of data collection frameworks, including providing data and expertise as resources and a public-private partnership frameworks are established.This grant will support the continued advancement of FDA's initiatives to support antimicrobial stewardship in veterinary settings. It will also support the National Action Plan objectives to engage the animal health community and relevant stakeholders to advance strategies intended to improve understanding of antimicrobial use and foster antimicrobial stewardship in animal agriculture.

This program provides funding to metropolitan cities like Fayetteville for community revitalization projects that benefit low- and moderate-income residents, support economic development, and improve public facilities and services.

The "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that focus on the development of innovative technologies for analyzing molecular or cellular aspects of cancer, with the goal of improving cancer biology research, early detection, diagnosis, treatment, control, epidemiology, and addressing health disparities related to cancer.

The "Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that focus on improving the quality of cancer samples through the development and validation of innovative technologies, which will help in preserving sample integrity, establishing quality control, and reducing variations in sample quality, ultimately enhancing cancer research, diagnosis, and treatment.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage existing NCI P30 centers to enhance their current research by integrating new technologies from the NCI Innovative Molecular Analysis Technologies program, with the goal of advancing cancer research and promoting scientific discovery.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage current NCI R01 research projects to incorporate new technologies from the NCI Innovative Molecular Analysis Technologies program, with the goal of enhancing their original research and speeding up scientific discoveries in cancer research.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage existing NCI P50 specialized centers to enhance their current cancer research by integrating new technologies or methods developed by the NCI Innovative Molecular Analysis Technologies program.

The "Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research" grant aims to fund the development of innovative technologies that enhance the quality of biological samples used in cancer research, by addressing issues related to sample degradation during collection, processing, and storage, and by establishing quality control measures.

The "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research" grant aims to encourage current NCI U01 research projects to incorporate new technologies from the NCI Innovative Molecular Analysis Technologies program, in order to enhance their original research and speed up scientific discoveries in cancer research.

This grant provides funding to improve living conditions and expand affordable housing options for low- and moderate-income residents in the City of Corona.

TheNational Institute of Allergy and Infectious Diseases (NIAID),intendstopublish a Notice of Funding Opportunity (NOFO) tosolicit applications for a Center of Excellence (CoE) for Systems Modeling of Infection and Immunity across Biological Scales that will: Develop and conduct innovative computational multi-scale modeling research for NIAID priority biomedical questions, including HIV/AIDS; Coordinate the NIAID and broader modeling community that conducts research on infectious- and immune-mediated diseases, through model and data sharing, opportunity funds, educational activities, and community-organizing activities; Conduct innovative research and coordination activities to improve data and model sharing in the NIAID and broader modeling community; Foster a diverse community of new and existing investigators dedicated to Infectious and Immune-mediated Disease (IID) multi-scale modelingand collaboration between experimental and computational scientists; Serve as point of contact to NIAID for the modeling community and pivot research activities to address acutely emerging NIAID needs, such as outbreaks, epidemics, or pandemics; Establish community development and educational opportunities in IID multi-scale modeling for students, post-doctoral fellows, and new/early-stage investigators; Enable new approaches for multi-scale model sharing and reproducibility aligned with theFAIR (Findable, Accessible, Interoperable, and Reusable) principles and theNIAID Data Ecosystem Portal. This Notice isbeing provided toallow potential applicants sufficient timetodevelop meaningful collaborations andprojects. Potentialapplicantsareencouraged tousethistimetodevelop leadership teams to cover the full range of expertise and experience to develop the coordinating cores and research projects that will represent and enable strong scientific and operational connections between the CoE and the larger IID modeling community. This NOFO will utilize theU54 activity code.Details for a pre-application webinar will be provided in the published NOFO.

The purpose of this Notice is to announce the intention of National Institutes of Neurological Disorders and Stroke (NINDS) to reissue RFA-NS-21-021 to solicit applications for research pursuing translational activities and small clinical studies to advance the development of low risk therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in Spring 2024 with an expected application due date in Summer 2024. This NOFO will utilize the R61/R33 activity code. Details of the planned NOFO are provided below.

This program provides federal funds to non-profits and local organizations to improve housing, economic opportunities, and living conditions for low- and moderate-income residents in Federal Way.

This Notice of Intent to Publish is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects for the following Notice of Funding Opportunity (NOFO), which is expected to be published in January 2024, with an anticipatedapplication receipt date in May 2024. The Brain Research through Advancing Innovative Neurotechnologies(BRAIN) Initiative intends to promote a new initiative by publishing a NOFO to solicit applications that would support development and preclinical testing, beginning withproof of concept,of next-generation recording and/or modulation devices for human use to further our understanding of the human central nervous system and treat nervous system disorders. This NOFO will utilize the R18 activity code. Details of the planned NOFO are provided below.